New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
13:15 EDTFRXFDA discloses Paragraph IV patent challenge to Forest Labs' Namenda XR
The FDA disclosed that the first substantially complete generic drug application containing a "Paragraph IV" patent certification for Namenda XR, which is marketed by Forest Labs, was submitted to the agency on June, 10 2013. The paragraph IV notice, dated March 6, was posted to the FDA's website. Reference Link
News For FRX From The Last 14 Days
Check below for free stories on FRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for FRX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use